Invokana Lawsuit Plaintiffs Gain Support From FDA Safety Announcements Regarding Side Effect Concerns

March 14, 2016 – – TheProductLawyers.com reports on news that the U.S. Food and Drug Administration (FDA) has issued a warning to the public regarding a new-generation, type-2 diabetes drug named Invokana. The SGLT2 class inhibitor drug was manufactured by pharmaceutical giant Johnson & Johnson’s subsidiary Janssen Pharmaceuticals. The drug in question has been linked through FDA adverse event reports to a serious and potentially life-threatening condition known as diabetic ketoacidosis.

Invokana (canagliflozin) works by helping type-2 diabetes patients to maintain their blood sugar levels by preventing the kidneys from reabsorbing excess sugar and instead using the organs to rid the body of that excess sugar through urination. The FDA’s recent public safety warning regarding the drug, however, informs consumers that it may cause diabetic ketoacidosis, which occurs when the body’s bloodstream contains too much toxic acid (ketones).

The FDA has instructed those currently using the drug to remain super-aware of any signs or symptoms that the dangerous condition may be developing. These conditions can include nausea and vomiting, extreme fatigue, confusion, trouble breathing, and pain within the abdominal cavity. Because the condition can cause patients to become comatose or die if untreated, the FDA is urging Invokana patients who feel they are experiencing even one of these issues to seek prompt medical attention.

The agency has indicated that at this time, they have received around 20 reports of Invokana patients developing diabetic ketoacidosis, and requiring hospitalization to treat their condition. Reportedly, most of the patients who were involved in these reports had used Invokana for approximately two weeks time before they began to suffer from symptoms. Diabetic ketoacidosis for Invokana patients has also been the subject for several recent lawsuits filed against Janssen.

Invokana is not the only drug to have been linked to these potential dangers, unfortunately. It was one of several new-generation diabetes drugs released in the SGLT2 inhibitor class, and other similar drugs have now been linked to similar health problems. These drugs include Invokamet, Jardiance, Glyxambi, Farxiga and Xigduo.

The FDA has noted that these potential discovered links will continue to be further investigated. During their announcement, they stated, “We are continuing to investigate this safety issue and will determine whether changes are needed in the prescribing information for this class of drugs.”

The attorneys of Banville Law are dedicated to helping provide the public with important information concerning Invokana. They sponsor the online resource website TheProductLawyers.com and also work to assist anyone who may have used the drug and suffered from health problems. These individuals are entitled to the important opportunity to explore their legal rights, as they may also be entitled to legal action and significant compensation. The attorneys of Banville Law are working to help those interested in pursuing justice by offering free legal consultations to affected parties at this time.

To contact the attorneys of Banville Law to request additional information or ask questions, please call 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008671